American Journal of Hypertension

Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes..  34:64-72. 2021

N-Terminal Pro-B-Type Natriuretic Peptide and Longitudinal Risk of Hypertension. 2020

C-reactive protein and hypertension incidence in black and white Americans: REasons for Geographic And Racial Differences in Stroke (REGARDS) study. 2020

Paradoxical increase of 24-hour urinary aldosterone levels in obese patients with resistant hypertension on a high salt diet. 2020

Twenty-Five-Year Changes in Office and Ambulatory Blood Pressure: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. 2020

Using predicted atherosclerotic cardiovascular disease risk for discrimination of awake or nocturnal hypertension.  33:1011-1020. 2020

Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study.  33:949-957. 2020

Reserpine substantially lowers blood pressure in patients with refractory hypertension: A proof-of-concept study.  33:741-747. 2020

Uric acid and hypertension: An update with recommendations.  33:583-594. 2020

Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.  32:1146-1153. 2019

Ethnic differences in nighttime melatonin and nighttime blood pressure: A study in European Americans and African Americans.  32:968-974. 2019

Health Behaviors, Nocturnal Hypertension, and Non-dipping Blood Pressure: The coronary artery risk development in young adults and jackson Heart study.  32:759-768. 2019

Serum Sodium and Pulse Pressure in SPRINT.  32:649-656. 2019

Blood Pressure Measurement Challenges in Severely Obese Patients.  32:139-140. 2019

Cardioprotective Effects of Paricalcitol Alone and in Combination with FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.  32:34-44. 2019

West African ancestry and nocturnal blood pressure in African Americans: The Jackson Heart Study.  31:706-714. 2018

Long-term effects of an intensive lifestyle intervention on electrocardiographic criteria for left ventricular hypertrophy: The look AHEAD trial.  31:541-548. 2018

11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension.  30:518-523. 2017

Cumulative exposure to systolic blood pressure during young adulthood through midlife and the urine albumin-to-creatinine ratio at midlife.  30:502-509. 2017

Psychosocial Correlates of Nocturnal Blood Pressure Dipping in African Americans: The Jackson Heart Study.  29:904-912. 2016

Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al., AJH 2014; 27(2):146-156.  29:780-781. 2016

Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study.  29:568-574. 2016

Clock genes explain a large proportion of phenotypic variance in systolic blood pressure and this control is not modified by environmental temperature.  29:132-140. 2016

Is isolated nocturnal hypertension a reproducible phenotype?.  29:33-38. 2016

Systolic blood pressure control among individuals with type 2 diabetes: A comparative effectiveness analysis of three interventions.  28:995-1009. 2015

Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the coronary artery risk development in young adults (CARDIA) study.  28:640-648. 2015

Is pulse pressure an independent risk factor for incident stroke, REasons for geographic and racial differences in stroke.  28:987-994. 2015

Nocturnal blood pressure in young adults and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) study.  28:1240-1247. 2015

Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.  27:720-726. 2014

Prehypertension and incident acute coronary heart disease in the reasons for geographic and racial differences in stroke (Regards) study.  27:245-251. 2014

Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: Challenges and lessons learned.  27:1052-1060. 2014

Hemodynamic and echocardiographic profiles in african american compared with white offspring of hypertensive parents: The HyperGEN study.  27:21-26. 2014

Is pulse pressure an independent risk factor for incident acute coronary heart disease events? the REGARDS study.  27:555-563. 2014

Blood pressure after recent stroke: Baseline findings from the secondary prevention of small subcortical strok.  26:1114-1122. 2013

Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease.  25:789-796. 2012

Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.  24:708-715. 2011

Moderate waist circumference and hypertension prevalence: The REGARDS study.  24:482-488. 2011

Prehypertension, racial prevalence and its association with risk factors: Analysis of the reasons for geographic and racial differences in stroke (REGARDS) study.  24:194-199. 2011

Adjusting adiposity and body weight measurements for height alters the relationship with blood pressure in children.  23:904-910. 2010

The association of cell cycle checkpoint 2 variants and kidney function: Findings of the family blood pressure program and the atherosclerosis risk in communities study.  22:552-558. 2009

Prenatal programming: Maybe not so hopeless after all?.  22:348. 2009

Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.  18:805-812. 2005

A summary of the effects of antihypertensive medications on measured blood pressure.  18:935-942. 2005

A unifying pathway for essential hypertension.  18:431-440. 2005

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.  18:287-294. 2005

Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study.  17:839-844. 2004

Determinants of radial artery pulse wave analysis in asymptomatic individuals.  17:647-653. 2004

Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process.  17:S23-S30. 2004

Genome scan for hypertension in nonobese African Americans: The National Heart, Lung, and Blood Institute Family Blood Pressure Program.  17:834-838. 2004

Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.  16:265-269. 2003

A Genome-Wide Linkage Analysis Investigating the Determinants of Blood Pressure in Whites and African Americans.  16:151-153. 2003

Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension.  16:51-58. 2003

Excess dietary glucose alters renal function before increasing arterial pressure and inducing insulin resistance.  15:773-779. 2002

Are there meaningful differences in blood pressure control with current antihypertensive agents?.  15:14S-21S. 2002

Obesity: Its time has come.  15:655-656. 2002

Arterial compliance abnormalities in isolated systolic hypertension.  14:1007-1011. 2001

Urinary excretion of vasoactive factors are correlated to sodium excretion.  14:1003-1006. 2001

Elevated potassium intake inhibits neointimal proliferation in the swine coronary artery.  14:879-886. 2001

Cardiovascular effects of estrogen..  14:186S-193S. 2001

The role of the central nervous system in NaCl-sensitive hypertension in spontaneously hypertensive rats..  14:155S-162S. 2001

Blood pressure and arterial compliance in young adults: The Minnesota Children's Blood Pressure Study.  14:200-205. 2001

Factors affecting blood pressure responses to diet: The vanguard study.  13:956-965. 2000

High potassium intake inhibits neointima formation in the rat carotid artery balloon injury model.  13:1014-1020. 2000

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study.  13:899-906. 2000

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint..  13:899-906. 2000

Insulin and hypertension in the NHLBI family heart study.  13:240-250. 2000

Newly emerging pharmacologic differences in angiotensin II receptor blockers.  13. 2000

Newly emerging pharmacologic differences in angiotensin II receptor blockers..  13:18S-24S. 2000

Treating multiple-risk hypertensive populations..  12:121S-129S. 1999

Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises.  12:653-664. 1999

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.  12:414-417. 1999

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension..  12:414-417. 1999

Management of the hypertensive patient with coronary artery disease..  12:56S-62S. 1999

Management of the hypertensive patient with coronary artery disease.  12:56S-62S. 1999

Treating multiple-risk hypertensive populations.  12:121-129. 1999

The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study..  11:192S-194S. 1998

Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension..  11:88S-94S. 1998

Case study.  11. 1998

Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.  11:31-40. 1998

Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension..  11:31-40. 1998

Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension.  11:88S-94S. 1998

Vascular compliance and cardiovascular disease: A risk factor or a marker?.  10:1175-1189. 1997

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.  10:735-742. 1997

Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension..  10:735-742. 1997

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group..  10:705-713. 1997

ALLHAT and calcium channel blockers [3].  10:142-143. 1997

ALLHAT and calcium channel blockers. ALLHAT Research Group..  10:142-143. 1997

Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.  10:68-76. 1997

Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742)).  10:1081. 1997

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods.  10:705-713. 1997

Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the coronary artery risk development in young adults (CARDIA) study.  9:915-923. 1996

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group..  9:342-360. 1996

Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).  9:342-360. 1996

Pressor and bradykardie effects of centrally administered relaxin in conscious rats.  8:375-381. 1995

Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats..  5:210-218. 1992

Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats.  5:210-218. 1992

Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats.  5:806-810. 1992

The calcium antagonists in the 1990s. An overview..  4:396S-405S. 1991

Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats..  4:449-455. 1991

Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats.  4:449-455. 1991

Diagnosis of renovascular hypertension after renal transplantation.  4:724S-730S. 1991

Report of the working party group on determining the radionuclide of choice.  4:747S-748S. 1991

The calcium antagonists in the 1990s an overview.  4:396S-405S. 1991

Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism..  3:179S-188S. 1990

Dietary ca²⁺prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.  3:179S-188S. 1990

Central mechanisms of hypertension..  2:477-485. 1989

Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats..  2:435-439. 1989

Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension..  2:154-157. 1989

Central mechanisms of hypertension.  2:477-485. 1989

Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.  2:435-439. 1989

Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension.  2:154-157. 1989